Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

被引：0
作者：
Radek Lakomy
Alexandr Poprach
Zbynek Bortlicek
Bohuslav Melichar
Renata Chloupkova
Rostislav Vyzula
Milada Zemanova
Katerina Kopeckova
Marek Svoboda
Ondrej Slaby
Igor Kiss
Hana Studentova
Jaroslav Juracek
Ondrej Fiala
Jindrich Kopecky
Jindrich Finek
Ladislav Dusek
Karel Hejduk
Tomas Buchler
机构：
[1] Masaryk Memorial Cancer Institute and Masaryk University,Department of Comprehensive Cancer Care and Faculty of Medicine
[2] Masaryk University,Institute of Biostatistics and Analyses, Faculty of Medicine
[3] Department of Oncology,Department of Oncology
[4] Palacky University Medical School and Teaching Hospital,Department of Oncology
[5] First Faculty of Medicine,Department of Oncology
[6] Charles University and General University Hospital,Department of Oncology, First Faculty of Medicine
[7] Second Faculty of Medicine,undefined
[8] Charles University and Motol University Hospital,undefined
[9] Charles University and University Hospital,undefined
[10] Department of Oncology,undefined
[11] Hradec Králové University Hospital and Faculty of Medicine,undefined
[12] Charles University,undefined
[13] Hradec Králové,undefined
[14] Charles University and Thomayer Hospital,undefined
来源：
BMC Cancer | / 17卷
关键词：
Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 187 条
[1]  
Escudier B(2016)Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v58-v68
[2]  
Porta C(2010)Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 4256-4265
[3]  
Schmidinger M(2013)Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 552-562
[4]  
Rioux-Leclercq N(2015)Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice J Oncol Pract 11 491-497
[5]  
Bex A(2012)Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database Med Oncol 29 3314-3320
[6]  
Motzer RJ(2012)Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study Ann Oncol 23 3137-3143
[7]  
Escudier B(2012)Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry Ann Oncol 23 395-401
[8]  
Oudard S(2012)Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma Med Oncol 29 3321-3324
[9]  
Hutson TE(2014)Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis Urol Oncol 32 569-575
[10]  
Porta C(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
12345678910